S 230815
Alternative Names: KCNT1 ASO; S-230815Latest Information Update: 03 Feb 2026
At a glance
- Originator Servier
- Class Antiepileptic drugs; Antisense oligonucleotides
- Mechanism of Action KCNT1 protein expression modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Epilepsy
Most Recent Events
- 21 Nov 2025 Phase-I/II clinical trials in Epilepsy (In neonates, In infants, In children, In adolescents) in France (Intrathecal) (CTIS2024-513332-17-00)
- 19 Nov 2025 Phase-I/II clinical trials in Epilepsy (In neonates, In infants, In children, In adolescents) in Spain (Intrathecal) (CTIS2024-513332-17-00)
- 18 Aug 2025 Servier plans a phase Ib/II KCNT1-DEE trial for Neurodevelopmental-disorders (In infants, In children, In adolescent) in France and US (Intrathecal) (CTIS2024-513332-17-00)